A Phase II Trial to Assess the Activity of NY-ES-O1 Targeted T Cells in Advanced Oesophagogastric Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ATTACK-OG; Y-ESO1OG
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.